Strengthening regional commitment to ensuring access to medical abortion medicines in WHO’s South-East Asia region: report of a participatory assessment and workshop
-
Published:2024-05-17
Issue:S1
Volume:20
Page:
-
ISSN:1742-4755
-
Container-title:Reproductive Health
-
language:en
-
Short-container-title:Reprod Health
Author:
Upadhyay Meera ThapaORCID, Fusire Terence, Loi Ulrika Rehnström, Sorhaindo Annik, Salahuddin Mohammed, Hossain Mohammed Ayub, Tshomo Tashi, Mulati Erna, Daisy Lovely, Anggraweni Dian Putri, Gultom Tumiur, Indrawati Fitri, Jenyfa Mariyam, Than Myint Myint, Bhattarai Bharat, Moonasinghe Loshan, Mathota Chaminda, Jitruknatee Anchalee, Cham Celeste, Ganatra Bela, Raina Neena
Abstract
Abstract
Background
In 2019, the World Health Organization identified improving access to safe abortion as an important priority toward improving sexual and reproductive health and rights and achieving Sustainable Development Goals. One strategy for addressing this priority is strengthening access to medicines for medical abortion. All 11 countries in the South-East Asia Region have some indications for legal abortion and permit post-abortion care. Therefore, strengthening access to medical abortion medicines is a reasonable strategy for improving access to safe abortion for the Region.
Methodology
We applied an adapted version of an existing World Health Organization landscape assessment protocol for the availability of medical abortion medicines at the country-level in the South-East Asia Region. We collected publicly available data on the existence of national health laws, policies, and standard treatment guidelines; inclusion of medical abortion medicines in the national essential medicines list; and marketing authorization status for medical abortion medicines for each country and verified by Ministries of health. The findings were once more presented, discussed and recommendations were formulated during regional technical consultation workshop. Each country teams participated in the process, and subsequently, the suggestions were validated by representatives from Ministries of Health..
Results
Few countries in the Region currently have national policies and guidelines for comprehensive safe abortion. However, either mifepristone-misoprostol in combination or misoprostol alone (for other indications) is included in national essential medicines lists in all countries except Indonesia and Sri Lanka. Few countries earmark specific public funds for procuring and distributing medical abortion commodities. In countries where abortion is legal, the private sector and NGOs support access to medical abortion information and medicines. Several countries only allow registered medical practitioners or specialists to administer medical abortion.
Conclusion
Following this rapid participatory assessment and technical consultation workshop, the World Health Organization South-East Asia Regional Technical Advisory and Sexual and Reproductive Health and Rights technical committee recommended priority actions for policy and advocacy, service delivery, and monitoring and evaluation, and indicated areas for support.
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Bearak J, Popinchalk A, Ganatra B, Moller A, Tunçlap Ö, Beavin C, Kwok L, Alkema L. Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990–2019. Lancet Glob Health. 2020;8:e1152–61. 2. Say L, Chou D, Gemmill A, Tunçlap Ö, Moller A, Daniels J, Gülmezoglu AM, Temmerman M, Alkema I. Global causes of maternal death: a WHO analysis. The Lancet. 2014;2(6):e323–33. 3. Lavelanet AF, Schlitt S, Johnson BR, et al. Global Abortion Policies Database: a descriptive analysis of the legal categories of lawful abortion. BMC Int Health Hum Rights. 2018;18:44. https://doi.org/10.1186/s12914-018-0183-1. 4. WHO. Global Abortion Policies Database. https://abortion-policies.srhr.org/?mapq=q1h 5. World Health Organization. Abortion care guideline. Geneva: World health Organization; 2022.
|
|